Prognostic and predictive phenotypic biomarkers have been identified for rPFS and OS in de novo mCSPC. The Two Onc Docs provide a brief overview of the the urothelial carcinoma, RCC, and prostate cancer presentations of note Dr. Armstrong previews updates related to STAMPEDE, ARANOTE, LITESPARK-005, AMBASSADOR, and others. 177Lu-PSMA-617 is a PSMA-targeted radioligand therapy in patients with mCRPC. Olaparib monotherapy can provide high and durable PSA50 response rates in patients with PCa and BRCA2 alterations. Enzalutamide was associated with improvements in OS, PCS, TTS, and TTR compared with abiraterone acetate. Dr. Gebrael discusses the impact of baseline bone pain on survival outcomes in mHSPC. A previous study found 64Cu-SAR-bisPSMA to be safe and effective in identifying prostate cancer lesions in patients with BCR. The study presented the results of cohorts 4 and 5 from the phase 2 KEYNOTE-199 study. Dr. Helfand explores the potential of Clarity's 64Cu-SAR-bisPSMA agent for prostate cancer imaging. Black patients are often under-represented in oncology clinical trials. Stockholm3 is a blood-based test for the detection of prostate cancer that has demonstrated beneficial detection rates. Dr. Kinnaird elaborates on some of the limitations of MRI and benefits of PET/CT staging for locoregional prostate cancer. AUC3 seeks to reshape the landscape of GU cancer management through interdisciplinary dialogue and consensus building. Multiple cycles of AcPSMA can cause side effects including salivary gland toxicity and xerostomia. There is a lack of research investigating associations between bone pain and OS in patients with mHSPC. The impact of potential comorbidities and concomitant medication interactions in ARPIs are not well understood. Dr. Rini talks about the exciting sessions and entertainment in store for guests at The Uromigos Live and Unplugged 2024. Data show that of patients with prostate cancer, Black men face higher incidence and mortality rates than White men. Researchers focused on the economic impact of disparities related to insurance coverage.